{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:17:29Z","timestamp":1790957849646,"version":"4.1.0"},"reference-count":70,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.3892\/or.2014.3270","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T13:48:12Z","timestamp":1402667292000},"page":"451-461","source":"Crossref","is-referenced-by-count":17,"title":["Clinical evidence of the relationship between aspirin and breast cancer risk (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"NADIA J.","family":"JACOBO-HERRERA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CARLOS","family":"P\u00c9REZ-PLASENCIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ELIZABETH","family":"CAMACHO-ZAVALA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GABRIELA FIGUEROA","family":"GONZ\u00c1LEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EDUARDO L\u00d3PEZ","family":"URRUTIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VER\u00d3NICA","family":"GARC\u00cdA-CASTILLO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEJANDRO","family":"ZENTELLA-DEHESA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,6,13]]},"reference":[{"key":"key20180107210109_b1-or-32-02-0451","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"key20180107210109_b2-or-32-02-0451","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S1470-2045(12)70246-2","article-title":"Breast cancer in Mexico: a growing challenge to health and the health system","volume":"13","author":"Ch\u00e1varri-Guerra","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20180107210109_b3-or-32-02-0451","first-page":"585","article-title":"Epidemiology of breast cancer","volume":"74","author":"Rodr\u00edguez-Cuevas","year":"2006","journal-title":"Ginecol Obstet Mex"},{"key":"key20180107210109_b4-or-32-02-0451","first-page":"172","article-title":"C\u00e1ncer de gl\u00e1ndula mamaria y met\u00e1stasis: un creciente problema de salud p\u00fablica en M\u00e9xico","volume-title":"Mensaje Bioqu\u00edmico","author":"Zentella-Dehesa","year":"2007"},{"key":"key20180107210109_b5-or-32-02-0451","doi-asserted-by":"crossref","first-page":"H2169","DOI":"10.1152\/ajpheart.00068.2009","article-title":"Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2","volume":"297","author":"Spallarossa","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key20180107210109_b6-or-32-02-0451","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2006.04.020","article-title":"Pathogenesis of cardiotoxicity induced by anthracyclines","volume":"33","author":"Elliott","year":"2006","journal-title":"Semin Oncol"},{"key":"key20180107210109_b7-or-32-02-0451","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/485S55a","article-title":"Metastasis: The rude awakening","volume":"485","author":"Rice","year":"2012","journal-title":"Nature"},{"key":"key20180107210109_b8-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1054\/bjoc.2000.1709","article-title":"Breast cancer and NSAID use: a meta-analysis","volume":"84","author":"Khuder","year":"2001","journal-title":"Br J Cancer"},{"key":"key20180107210109_b9-or-32-02-0451","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1742-1241.2007.01668.x","article-title":"NSAIDs and breast cancer: a possible prevention and treatment strategy","volume":"62","author":"Agrawal","year":"2008","journal-title":"Int J Clin Pract"},{"key":"key20180107210109_b10-or-32-02-0451","first-page":"1586","article-title":"Association of aspirin and nonsteroidal anti-inflammatory drugs use with breast cancer","volume":"11","author":"Johnson","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180107210109_b11-or-32-02-0451","first-page":"6096","article-title":"Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women\u2019s Health Initiative","volume":"63","author":"Harris","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107210109_b12-or-32-02-0451","first-page":"3177","article-title":"Aspirin use and mortality from cancer in a prospective cohort study","volume":"24","author":"Ratnasinghe","year":"2004","journal-title":"Anticancer Res"},{"key":"key20180107210109_b13-or-32-02-0451","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/dji140","article-title":"Nonsteroidal anti-inflammatory drugs use and breast cancer risk by stage and hormone receptor status","volume":"97","author":"Marshall","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20180107210109_b14-or-32-02-0451","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/jnci\/88.14.988","article-title":"Prospective study of regular aspirin use and the risk of breast cancer","volume":"88","author":"Egan","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"key20180107210109_b15-or-32-02-0451","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/aje\/kwm216","article-title":"Nonsteroidal anti-inflammatory drug use and breast cancer risk: subgroup findings","volume":"166","author":"Kirsh","year":"2007","journal-title":"Am J Epidemiol"},{"key":"key20180107210109_b16-or-32-02-0451","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/jama.291.20.2433","article-title":"Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk","volume":"291","author":"Terry","year":"2004","journal-title":"JAMA"},{"key":"key20180107210109_b17-or-32-02-0451","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/aje\/kwi182","article-title":"Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer: the case-control surveillance study revisited","volume":"162","author":"Zhang","year":"2005","journal-title":"Am J Epidemiol"},{"key":"key20180107210109_b18-or-32-02-0451","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6600760","article-title":"A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin","volume":"88","author":"Friis","year":"2003","journal-title":"Br J Cancer"},{"key":"key20180107210109_b19-or-32-02-0451","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CEJ.0b013e3282b6fd55","article-title":"Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study","volume":"17","author":"Friis","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"key20180107210109_b20-or-32-02-0451","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-dose aspirin in the primary prevention of cancer. The Women\u2019s Health Study: a randomized controlled trial","volume":"294","author":"Cook","year":"2005","journal-title":"JAMA"},{"key":"key20180107210109_b21-or-32-02-0451","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1055-9965.261.14.1","article-title":"Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort","volume":"14","author":"Jacobs","year":"2005","journal-title":"Cancer Epidem Biomarkers Prev"},{"key":"key20180107210109_b22-or-32-02-0451","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jnci\/djk132","article-title":"A large cohort study of long-term daily use of adult strength aspirin and cancer incidence","volume":"99","author":"Jacobs","year":"2007","journal-title":"J Nat Cancer Inst"},{"key":"key20180107210109_b23-or-32-02-0451","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00001648-199403000-00003","article-title":"Aspirin use and lung, colon, and breast cancer incidence in a prospective study","volume":"5","author":"Schreinemachers","year":"1994","journal-title":"Epidemiology"},{"key":"key20180107210109_b24-or-32-02-0451","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jnci\/djk200","article-title":"Association of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with cancer incidence and mortality","volume":"99","author":"Bardia","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"key20180107210109_b25-or-32-02-0451","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1081\/CNV-120002490","article-title":"Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer","volume":"20","author":"Badawi","year":"2002","journal-title":"Cancer Invest"},{"key":"key20180107210109_b26-or-32-02-0451","doi-asserted-by":"crossref","first-page":"L981","DOI":"10.1152\/ajplung.00239.2003","article-title":"Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblast: implications for lung inflammation and cancer","volume":"287","author":"Martey","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key20180107210109_b27-or-32-02-0451","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9665-x","article-title":"NSAID use and breast cancer risk in the VITAL cohort","volume":"109","author":"Ready","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107210109_b28-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/aje\/kwm195","article-title":"Nonsteroidal anti-inflammatory drugs and breast cancer risk: the multiethnic cohort","volume":"166","author":"Gill","year":"2007","journal-title":"Am J Epidemol"},{"key":"key20180107210109_b29-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/bmj.320.7250.1642","article-title":"Effect of anti-inflammatory drugs overall risk of common cancer: case-control study in general practice research database","volume":"320","author":"Langman","year":"2000","journal-title":"BMJ"},{"key":"key20180107210109_b30-or-32-02-0451","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1023\/B:CACO.0000007973.59863.66","article-title":"Association between nonsteroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast","volume":"14","author":"Moorman","year":"2003","journal-title":"Cancer Causes Control"},{"key":"key20180107210109_b31-or-32-02-0451","first-page":"1213","article-title":"Nonsteroidal anti-inflammatory drug used and breast cancer risk","volume":"10","author":"Cotterchio","year":"2001","journal-title":"Cancer Epidemiol Biormarkers Prev"},{"key":"key20180107210109_b32-or-32-02-0451","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.bjc.6602003","article-title":"Risk of breast cancer among users of aspirin and other anti-inflammatory drugs","volume":"91","author":"Garc\u00eda Rodr\u00edguez","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180107210109_b33-or-32-02-0451","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000084818","article-title":"Association of regular aspirin use and breast cancer risk","volume":"68","author":"Swede","year":"2005","journal-title":"Oncology"},{"key":"key20180107210109_b34-or-32-02-0451","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1055-9965.EPI-06-0667","article-title":"IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States","volume":"16","author":"Slattery","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180107210109_b35-or-32-02-0451","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0304-3835(01)00569-9","article-title":"Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues","volume":"171","author":"Hojo","year":"2001","journal-title":"Cancer Lett"},{"key":"key20180107210109_b36-or-32-02-0451","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0009-9120(01)00220-X","article-title":"Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis","volume":"34","author":"Maass","year":"2001","journal-title":"Clin Biochem"},{"key":"key20180107210109_b37-or-32-02-0451","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/02841860500516584","article-title":"Restoration by aspirin of impaired plasma maspin level in human breast cancer","volume":"45","author":"Girish","year":"2006","journal-title":"Acta Oncol"},{"key":"key20180107210109_b38-or-32-02-0451","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1349-7006.2010.01655.x","article-title":"Acetylsalicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients","volume":"101","author":"Bhattacharyya","year":"2010","journal-title":"Cancer Sci"},{"key":"key20180107210109_b39-or-32-02-0451","first-page":"1592","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"key20180107210109_b40-or-32-02-0451","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2010.04131.x","article-title":"The platelet contribution to cancer progression","volume":"9","author":"Bambace","year":"2011","journal-title":"J Thromb Haemostat"},{"key":"key20180107210109_b41-or-32-02-0451","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nature Rev Cancer"},{"key":"key20180107210109_b42-or-32-02-0451","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nature Rev Cancer"},{"key":"key20180107210109_b43-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2009.22.7918","article-title":"Aspirin intake and survival after breast cancer","volume":"28","author":"Holmes","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107210109_b44-or-32-02-0451","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","article-title":"Cyclooxygenases: structural, cellular, and molecular biology","volume":"69","author":"Smith","year":"2000","journal-title":"Annu Rev Biochem"},{"key":"key20180107210109_b45-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.06.014","article-title":"Cyclooxygenases in cancer: progress and perspective","volume":"215","author":"Zha","year":"2004","journal-title":"Cancer Lett"},{"key":"key20180107210109_b46-or-32-02-0451","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/bega.2001.0237","article-title":"COX-2 inhibition and prevention of cancer","volume":"15","author":"Giercksky","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"key20180107210109_b47-or-32-02-0451","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc1801","article-title":"Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics","volume":"6","author":"Ulrich","year":"2006","journal-title":"Nature Review Cancer"},{"key":"key20180107210109_b48-or-32-02-0451","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1615\/JEnvironPatholToxicolOncol.v21.i2.130","article-title":"Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risk","volume":"21","author":"Moran","year":"2002","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"key20180107210109_b49-or-32-02-0451","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0049-0172(97)80046-7","article-title":"Mechanism of action of aspirin-like drugs","volume":"26","author":"Vane","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"key20180107210109_b50-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4065\/75.10.1027","article-title":"The \u201caspirin\u201d of the new millenium: cyclooxigenase-2 inhibitors","volume":"75","author":"Buttar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"key20180107210109_b51-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(09)60243-9","article-title":"Aspirin, salicylates, and cancer","volume":"373","author":"Elwood","year":"2009","journal-title":"Lancet"},{"key":"key20180107210109_b52-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bjc.2011.289","article-title":"Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?","volume":"105","author":"Langley","year":"2011","journal-title":"Br J Cancer"},{"key":"key20180107210109_b53-or-32-02-0451","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2006.01.003","article-title":"Cyclooygenase-2 as a target for anticancer drug development","volume":"59","author":"Meric","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107210109_b54-or-32-02-0451","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jnci\/90.6.455","article-title":"Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer","volume":"90","author":"Hwang","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"key20180107210109_b55-or-32-02-0451","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-8674(00)81664-5","article-title":"PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs","volume":"99","author":"He","year":"1999","journal-title":"Cell"},{"key":"key20180107210109_b56-or-32-02-0451","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdf125","article-title":"Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention","volume":"13","author":"Davies","year":"2002","journal-title":"Ann Oncol"},{"key":"key20180107210109_b57-or-32-02-0451","doi-asserted-by":"crossref","first-page":"32943","DOI":"10.1074\/jbc.273.49.32943","article-title":"Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase\/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways","volume":"273","author":"Subbaramaiah","year":"1998","journal-title":"J Biol Chem"},{"key":"key20180107210109_b58-or-32-02-0451","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3835(99)00050-6","article-title":"Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens","volume":"140","author":"Brueggemeier","year":"1999","journal-title":"Cancer Lett"},{"key":"key20180107210109_b59-or-32-02-0451","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"key20180107210109_b60-or-32-02-0451","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/sj.bjc.6602942","article-title":"COX inhibitors and breast cancer","volume":"94","author":"Mazhar","year":"2006","journal-title":"Br J Cancer"},{"key":"key20180107210109_b61-or-32-02-0451","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10552-006-0033-7","article-title":"Aspirin and cancer risk: an updated quantitative review to 2005","volume":"17","author":"Bosetti","year":"2006","journal-title":"Cancer Causes Control"},{"key":"key20180107210109_b62-or-32-02-0451","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01.gco.0000192972.54105.cf","article-title":"Aspirin and NSAIDs: effects in breast and ovarian cancers","volume":"18","author":"Crew","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"key":"key20180107210109_b63-or-32-02-0451","first-page":"3","article-title":"Molecular pathology of cyclooxygenase-2 in neoplasia","volume":"30","author":"Fosslien","year":"2000","journal-title":"Ann Clin Lab Sci"},{"key":"key20180107210109_b64-or-32-02-0451","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00008469-200212000-00005","article-title":"Aspirin and cancer risk: an update to 2001","volume":"11","author":"Bosetti","year":"2002","journal-title":"Eur J Cancer Prev"},{"key":"key20180107210109_b65-or-32-02-0451","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/erc.0.0080097","article-title":"Cyclooxygenase-2: a target for the prevention and treatment of breast cancer","volume":"8","author":"Howe","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"key20180107210109_b66-or-32-02-0451","first-page":"2141","article-title":"Cyclooxygenase-2 P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?","volume":"21","author":"Ratnasinghe","year":"2001","journal-title":"Anticancer Res"},{"key":"key20180107210109_b67-or-32-02-0451","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/bcr437","article-title":"Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo","volume":"4","author":"Streuli","year":"2002","journal-title":"Breast Cancer Res"},{"key":"key20180107210109_b68-or-32-02-0451","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2005.11.049","article-title":"Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer","volume":"101","author":"Solomon","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20180107210109_b69-or-32-02-0451","first-page":"2093","article-title":"Regulation of inflammation and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages","volume":"28","author":"Burnett","year":"2008","journal-title":"Anticancer Res"},{"key":"key20180107210109_b70-or-32-02-0451","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bcp.2008.09.020","article-title":"Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity","volume":"77","author":"Spitz","year":"2009","journal-title":"Biochem Pharmacol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3270\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T07:39:44Z","timestamp":1689320384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,13]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,6,13]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.3892\/or.2014.3270"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3270","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,13]]}}}